OLD National Bancorp IN Purchases Shares of 1,609 Repligen Co. (NASDAQ:RGEN)

OLD National Bancorp IN purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 1,609 shares of the biotechnology company’s stock, valued at approximately $289,000.

Several other institutional investors have also added to or reduced their stakes in RGEN. LRT Capital Management LLC lifted its position in shares of Repligen by 9.6% in the 4th quarter. LRT Capital Management LLC now owns 5,707 shares of the biotechnology company’s stock worth $1,026,000 after purchasing an additional 502 shares during the period. Signaturefd LLC lifted its position in shares of Repligen by 48.4% in the 4th quarter. Signaturefd LLC now owns 417 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 136 shares during the period. Verdence Capital Advisors LLC lifted its position in shares of Repligen by 36.7% in the 4th quarter. Verdence Capital Advisors LLC now owns 2,956 shares of the biotechnology company’s stock worth $531,000 after purchasing an additional 793 shares during the period. abrdn plc lifted its position in shares of Repligen by 1.4% in the 4th quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after purchasing an additional 71 shares during the period. Finally, NBW Capital LLC increased its stake in shares of Repligen by 8.7% in the 4th quarter. NBW Capital LLC now owns 33,038 shares of the biotechnology company’s stock worth $5,940,000 after acquiring an additional 2,650 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In other Repligen news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Anthony Hunt sold 16,707 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO James Bylund sold 4,373 shares of the business’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares in the company, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock valued at $5,039,532 over the last 90 days. 1.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several research reports. KeyCorp increased their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Stifel Nicolaus increased their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $196.70.

Repligen Stock Down 1.3 %

NASDAQ:RGEN opened at $165.66 on Friday. The firm has a 50-day simple moving average of $185.05 and a two-hundred day simple moving average of $173.47. Repligen Co. has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The firm has a market cap of $9.25 billion, a P/E ratio of 230.09, a P/E/G ratio of 5.50 and a beta of 1.02. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The firm had revenue of $155.74 million during the quarter, compared to analyst estimates of $155.38 million. During the same period in the previous year, the business posted $0.68 earnings per share. The business’s revenue for the quarter was down 16.6% on a year-over-year basis. Analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.